• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

    FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

  2. U.S. Hot Stocks: Hot Stocks to Watch

    U.S. Hot Stocks: Hot Stocks to Watch

  3. Charting the October technical breakdown -- -2-

    Charting the October technical breakdown -- -2-

  4. UPDATE: 11 stocks rising the most as the market heads toward a correction

    UPDATE: 11 stocks rising the most as the market heads toward a correction

  5. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

  6. Everything you need to know about investing you learned in grade school

    Everything you need to know about investing you learned in grade school

  7. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  8. How Did Facebook End Up in the S&P 500?

    We dive into the process for adding companies and booting them from the iconic index.

  9. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  10. Managing Expectations, Part II

    On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.